Smoore International Not Listed as Huabao's Main Client

Business by 2FIRSTS.ai

Dec.06.2023

Smoore International Not Listed as Huabao's Main Client

Huabao Shares denies Smoore International as its main client, clarifies on investor platform.

An investor asked on the investor interaction platform: Is Smoore International the company's main client?

Huabao Group (300741.SZ) stated on December 4th on an investor interaction platform that Smoore International is currently not included among the company's main clients.

Also Read:

[1] Smoore Announces FEELM 2.0: Double the Puffs, Half the Cost

[2] Smoore International Reports Decreased Financial Performance in 2023

#Asia #Market #China #smoore #International

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

KT&G Q3 Net Profit Up 73%; Overseas NGP Revenue Nearly Doubles, Nicotine Pouch Expansion Set to Launch Globally

KT&G reported its Q3 2025 financial results, posting revenue of KRW 1.83 trillion (≈USD 1.31 billion) and a 73.4% year-over-year surge in net profit—marking the company’s highest operating profit in five years. The Next Generation Product (NGP) segment performed strongly, generating KRW 279.1 billion (≈USD 199 million) in revenue, with overseas NGP sales more than doubling year-over-year.

Nov.06

Vietnam Drafts Administrative Penalties for E-Cigarette Use, Setting Fines up to USD 380

Vietnam plans to formalise penalties for e-cigarette and heated tobacco use under a draft decree. Individual users could be fined VND 3–5 million (USD 114–190), while premises allowing use face fines up to VND 10 million (USD 380). Higher penalties apply to business violations.

Dec.25 by 2FIRSTS.ai

Imperial Brands Urges Retailers to Engage in Government Consultation on Tobacco and Vapes Bill

Imperial Brands is calling on UK retailers to take part in the Government’s consultation on the Tobacco and Vapes Bill, which will shape a new licensing framework for nicotine product sales across England, Wales and Northern Ireland. The Department of Health and Social Care’s call for evidence closes on 3 December 2025. Imperial Brands stresses this is a key chance for retailers to influence policy, support fair competition, and help curb illicit sales.

Nov.04

Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement

In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.